Written questions by Pitcher.

Whether he plans to collect or publish data on the number of people whose work capability is affected by migraine or related headache disorders.

Awaiting answer.

What assessment his Department has made of the impact of migraine on levels of employment, absenteeism and economic inactivity in sufferers.

Awaiting answer.

What steps his Department is taking to encourage employers to provide reasonable workplace support for employees affected by migraine.

Awaiting answer.

If he will ensure that the Government provides, by 16 July 2026, the information requested by the Patient Safety Commissioner on (a) action taken in response to the Hughes Report, (b) outstanding steps required before Ministers can decide on redress and (c) a timetable for the Government’s full response, including on the establishment of compensation schemes for those harmed by pelvic mesh and sodium valproate.

Awaiting answer.

What steps his Department is taking to ensure that patients can access the most effective innovations for migraine.

Awaiting answer.

What steps his Department is taking to help improve outcomes for people living with migraine.

Awaiting answer.

What recent discussions he has had with the Secretary of State for Health and Social Care on cross-government support for people whose ability to work is affected by migraine.

Awaiting answer.

What guidance his Department provides to NHS and local authority professionals on responsibility for commissioning specialist night-time safety equipment for children with complex developmental dis

Awaiting answer.

Whether his Department plans to commission updated research into the long-term health effects of Poly Implant Prothèse breast implants on women.

The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is not currently funding any specific research into long-term health effects of Poly Implant Prothèse breast (PIP) implants but welcomes fundi...

What evidence the Department has assessed on the number and proportion of patients who develop impulse control disorders while taking dopamine agonists and subsequently (a) continue dopamine agonis

Awaiting answer.

What data national bodies hold on (a) the number and proportion of people prescribed dopamine agonists who self-report impulse control disorders and (b) the number and proportion whose impulse cont

Awaiting answer.

What data the Department holds on the average age at (a) initiation of dopamine agonist therapy, (b) first report or diagnosis of an impulse control disorder while taking a dopamine agonist and (c)

Awaiting answer.

What data the Department holds on (a) the average length of time patients remain on dopamine agonists or partial dopamine agonists for each licensed indication, (b) the proportion of patients who r

Awaiting answer.

What data the Department holds on the proportion of patients with restless legs syndrome treated with dopamine agonists who have co-existing neurodevelopmental or psychiatric diagnoses, including a

Awaiting answer.

What data the Department holds on the proportion of patients with restless legs syndrome alone, compared with patients with restless legs syndrome and attention deficit hyperactivity disorder, auti

Awaiting answer.

What information his Department holds on (a) the likelihood of patients who develop one dopamine agonist-associated impulse control disorder developing additional impulse control disorders and (b)

Awaiting answer.

What information national pharmacovigilance systems and clinical datasets provide on the range and relative frequency of withdrawal symptoms associated with dopamine agonist discontinuation, includ

Awaiting answer.

What assessment the Department has made of risk factors for dopamine agonist-induced impulse control disorders, including age, renal impairment, duration of exposure, cumulative dose, polypharmacy,

Awaiting answer.

What evidence the Department has assessed on the average time from initiating a dopamine agonist, or increasing its dose, to (a) the onset or first report of impulse control disorder symptoms and (

Awaiting answer.

What assessment his Department has made of the use of artificial intelligence and digital tools within the NHS and the Medicines and Healthcare products Regulatory Agency to (a) detect potential do

Awaiting answer.